Sithara Vivek1, Heather Hammond Nelson2,3, Anna E Prizment2,4, Jessica Faul5, Eileen M Crimmins6, Bharat Thyagarajan7,8,9. 1. Laboratory Medicine and Pathology, Medical School, University of Minnesota, Minneapolis, MN, USA. 2. Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA. 3. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA. 4. Division of Hematology, Oncology and Transplantation, Medical School, University of Minnesota, Minneapolis, MN, USA. 5. Institute for Social Research, Survey Research Center, University of Michigan, Ann Arbor, MI, USA. 6. Davis School of Gerontology, University of Southern California, Los Angeles, CA, USA. 7. Laboratory Medicine and Pathology, Medical School, University of Minnesota, Minneapolis, MN, USA. thya0003@umn.edu. 8. Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA. thya0003@umn.edu. 9. Department of Laboratory Medicine and Pathology, University of Minnesota, Moos Tower 1-136, 515 Delaware Street SE, Minneapolis, MN, 55455, USA. thya0003@umn.edu.
Abstract
PURPOSE: The higher prevalence of cognitive impairment/ dementia among cancer survivors is likely multifactorial. Since both exposures to cytomegalovirus (CMV) and inflammation are common among elderly cancer survivors, we evaluated their contribution towards dementia. METHODS: Data from 1387 cancer survivors and 7004 participants without cancer in the 2016 wave of the Health and Retirement Study (HRS) was used in this study. Two inflammatory biomarkers, C-reactive protein (CRP) and neutrophil-lymphocyte ratio (NLR), were used to create an inflammation score. We used survey logistic regression adjusted for survey design parameters. RESULTS: CMV seropositivity was not associated with cognitive impairment among cancer survivors (p = 0.2). In addition, inflammation was associated with elevated odds of cognitive impairment (OR = 2.2, 95% CI [1.2, 4.2]). Cancer survivors who were both CMV seropositive and had increased inflammation had the highest odds of cognitive impairment compared to those who were CMV seronegative and had low inflammation (OR = 3.8, 95% CI [1.5, 9.4]). The stratified analysis among cancer survivors showed this association was seen only among cancer survivors in whom the cancer was diagnosed within three years of measurement of inflammation score and CMV serostatus (OR = 18.5; 95% CI [6.1, 56.1]). CONCLUSION: The CMV seropositivity and high inflammation was associated with higher cognitive impairment among cancer survivors. The stronger associations seen among cancer survivors diagnosed within the last three years suggest that strategies to reduce CMV activation and inflammation during or immediately after cancer treatment may be important in reducing the prevalence of cognitive impairment/ dementia among cancer survivors.
PURPOSE: The higher prevalence of cognitive impairment/ dementia among cancer survivors is likely multifactorial. Since both exposures to cytomegalovirus (CMV) and inflammation are common among elderly cancer survivors, we evaluated their contribution towards dementia. METHODS: Data from 1387 cancer survivors and 7004 participants without cancer in the 2016 wave of the Health and Retirement Study (HRS) was used in this study. Two inflammatory biomarkers, C-reactive protein (CRP) and neutrophil-lymphocyte ratio (NLR), were used to create an inflammation score. We used survey logistic regression adjusted for survey design parameters. RESULTS: CMV seropositivity was not associated with cognitive impairment among cancer survivors (p = 0.2). In addition, inflammation was associated with elevated odds of cognitive impairment (OR = 2.2, 95% CI [1.2, 4.2]). Cancer survivors who were both CMV seropositive and had increased inflammation had the highest odds of cognitive impairment compared to those who were CMV seronegative and had low inflammation (OR = 3.8, 95% CI [1.5, 9.4]). The stratified analysis among cancer survivors showed this association was seen only among cancer survivors in whom the cancer was diagnosed within three years of measurement of inflammation score and CMV serostatus (OR = 18.5; 95% CI [6.1, 56.1]). CONCLUSION: The CMV seropositivity and high inflammation was associated with higher cognitive impairment among cancer survivors. The stronger associations seen among cancer survivors diagnosed within the last three years suggest that strategies to reduce CMV activation and inflammation during or immediately after cancer treatment may be important in reducing the prevalence of cognitive impairment/ dementia among cancer survivors.
Authors: Alan J Gow; Charlotte M Firth; Rowan Harrison; John M Starr; Paul Moss; Ian J Deary Journal: Neurobiol Aging Date: 2013-02-22 Impact factor: 4.673
Authors: Kristine Yaffe; Mary Haan; Terri Blackwell; Elena Cherkasova; Rachel A Whitmer; Nancy West Journal: J Am Geriatr Soc Date: 2007-05 Impact factor: 5.562
Authors: Marianne J Engelhart; Mirjam I Geerlings; John Meijer; Amanda Kiliaan; Annemieke Ruitenberg; John C van Swieten; Theo Stijnen; Albert Hofman; Jacqueline C M Witteman; Monique M B Breteler Journal: Arch Neurol Date: 2004-05
Authors: Michael D Hurd; Paco Martorell; Adeline Delavande; Kathleen J Mullen; Kenneth M Langa Journal: N Engl J Med Date: 2013-04-04 Impact factor: 91.245
Authors: Reinhold Schmidt; Helena Schmidt; J David Curb; Kamal Masaki; Lon R White; Lenore J Launer Journal: Ann Neurol Date: 2002-08 Impact factor: 10.422
Authors: Lajos Pusztai; Tito R Mendoza; James M Reuben; Monica M Martinez; Jie S Willey; Juanita Lara; Abdul Syed; Herbert A Fritsche; Eduardo Bruera; Daniel Booser; Vicente Valero; Banu Arun; Nuhad Ibrahim; Edgardo Rivera; Melanie Royce; Charles S Cleeland; Gabriel N Hortobagyi Journal: Cytokine Date: 2004-02-07 Impact factor: 3.861
Authors: C E Teunissen; M P J van Boxtel; H Bosma; E Bosmans; J Delanghe; C De Bruijn; A Wauters; M Maes; J Jolles; H W M Steinbusch; J de Vente Journal: J Neuroimmunol Date: 2003-01 Impact factor: 3.478
Authors: Kimberly D van der Willik; Vincent Koppelmans; Michael Hauptmann; Annette Compter; M Arfan Ikram; Sanne B Schagen Journal: Breast Cancer Res Date: 2018-11-15 Impact factor: 6.466